Report of the expert committee on the diagnosis and classification of diabetes mellitus

Diabetes Care

Volumn 24, Issue SUPPL. 1, 2001, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; GLUCAGON; GLUCOCORTICOID; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; NICOTINIC ACID; PENTAMIDINE; VACOR;

ARTICLE; DIABETES MELLITUS; DISEASE CLASSIFICATION; ENDOCRINE DISEASE; GENETIC DISORDER; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATHOGENESIS; PREGNANCY DIABETES MELLITUS; PREVALENCE; VIRUS INFECTION;

EID: 0035160931     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (144)

1. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
2. Malnutrition and diabetes in the tropics
3. The pathogenesis of insulin dependent diabetes
4. Autoantibodies in newly diagnosed diabetic children with immunoprecipitate human pancreatic islet cell proteins
5. Are insulin autoantibodies marker for insulin-dependent mellitus?
6. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent mellitus
7. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM: Studies with identical twins
8. 65 autoantibodies increase the predictability but not the sensitivity of islet cell and insulin autoantibodies for developing insulin dependent diabetes mellitus
9. Do glutamic acid decarboxylase antibodies improve the prediction of IDDM in first-degree relatives at risk for IDDM?
10. Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase
11. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus
12. Identification of a second transmembrane protein tyrosine phosphatase, IA-2β, as an autoantigen in insulin-dependent diabetes mellitus: Precursor of the 37-kDa tryptic fragment
13. Age and family relationship accentuate the risk of IDDM in relatives of patients with insulin dependent diabetes
14. Although DR3-DQB1* may be associated with multiple component diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-DQB1I0302 haplotype is implicated only in beta cell autoimmunity
15. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
16. Insulin sensitive and insulin resistant variants in IDDM
17. Nonketotic diabetes mellitus: Insulin deficiency or insulin resistance?
18. Insulin action and resistance in obesity and non-insulin-dependent type II diabetes mellitus
19. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes
20. Insulin deficiency and insulin resistance interaction in diabetes: Estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations
21. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus
22. Relationship between degree of obesity and in vivo insulin action in man
23. Relationship of body fat distribution to metabolic complications of obesity
24. Insulin therapy for diabetic ketoacidosis
25. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4
26. Diabetic ketoacidosis in obese African-Americans
27. Impaired glucose tolerance in the U.S. population
28. Kelly west lecture 1991: Challenges in diabetes epidemiology: From west to the rest
29. Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance or normal glucose tolerance
30. The association of glycemia and cause-specific mortality in a diabetic population
31. NIDDM and its metabolic control predict coronary heart disease in elderly subjects
32. Long-term glycemic control relates to mortality in type II diabetes
33. Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
34. Non-insulin-dependent diabetes mellitus: A genetically programmed failure of the beta cell to compensate for insulin resistance
35. Insulin treatment reverses the insulin resistance of type II diabetes mellitus
36. Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus
37. Mechanism of improvement in glucose metabolism after chronic glyburide therapy
38. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus
39. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients
40. Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins
41. Diabetes in identical twins
42. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree
43. Altered insulin secretory response to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12
44. Assessment of insulin sensitivity in glucokinase-deficient subjects
45. A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q
46. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY 3)
47. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus
48. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus
49. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q
50. Mutations in the hepatocyte factor-4α gene in maturity-onset diabetes of the young (MODY 1)
51. Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA
52. Mutation in mitochondrial tRNA (Leu(URR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness
53. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA
54. Mitochondrial DNA and disease
55. Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin
56. Familial hyperproinsulinemia: Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion
57. A structurally abnormal insulin causing human diabetes
58. B24]insulin
59. Diabetes due to secretion of an abnormal insulin
60. The syndromes of insulin resistance and acanthosis nigricans
61. Lilly Lecture: Molecular mechanisms of insulin resistance: Lessons from patients with mutations in the insulin-receptor gene
62. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
63. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome
64. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma
65. Insulin secretion and action in patients with pancreatic cancer
66. Metabolic control and B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis
67. Prevalence of genetic haemochromatosis among diabetic patients
68. Glucose intolerance in cystic fibrosis
69. The ketoacidosis-resistance in fibro-calculous-pancreatic-diabetes
70. Cushing's syndrome
71. The acromegaly syndrome
72. Long-term results in 64 patients operated upon for pheochromocytoma
73. Non-insulin dependent diabetes mellitus secondary to other endocrine disorders
74. Hypertension, the potassium ion and impaired carbohydrate tolerance
75. Drug-induced disorders of glucose tolerance
76. Effects of drugs on glucose tolerance in non-insulin-dependent diabetes (parts I and II)
77. Diabetes mellitus following pentamidine-induced hypoglycemia in humans
78. Pentamidine-induced derangements of glucose homeostasis
79. Diabetes mellitus associated with autonomic and peripheral neuropathy after Vacor poisoning: A review
80. Inhibition of mitochondrial complex I may account for IDDM induced by intoxication with rodenticide Vacor
81. Development of type 1 diabetes mellitus during interferon Alpha theraphy for chonic HCV hepatitis
82. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis
83. High frequency of diabetes mellitus in young patients with congenital rubella
84. Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type I) diabetes mellitus
85. Relationship between serum insulin antibodies, islet cell antibodies and Coxsackie-B4 and mumps virus-specific antibodies at the clinical manifestation of type I (insulin-dependent) diabetes
86. Association of cytomegalovirus infection with autoimmune type 1 diabetes
87. Autoantibodies to GABA-nergic neurons and pancreatic beta cells in stiffman syndrome
88. Genetic syndromes associated with glucose intolerance
89. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome
90. Summary and recommendations of the Third International Workshop-Conference on Gestational Diabetes Mellitus
91. The epidemiology of diabetes and pregnancy in the U.S., 1988
92. Gestational diabetes
93. Intensified versus conventional management of gestational diabetes
94. Influence of diagnostic criteria on the incidence of gestational diabetes and perinatal morbidity
95. Obstetric complications
96. Criteria for the oral glucose tolerance test in pregnancy
97. The Boston Gestational Diabetes Studies: Review and perspective
98. Diabetes after GDM
99. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus
100. Gestational diabetes: Predictors of subsequent disordered glucose metabolism
101. Gestational diabetes: The prevalence of glucose intolerance and diabetes mellitus in the first two months postpartum
102. Diabetes and pregnancy
103. Criteria for screening tests for gestational diabetes
104. Do the current standards for glucose tolerance testing in pregnancy represent a valid conversion of O'Sullivan's original criteria?
105. Are the current ACOG glucose tolerance test criteria sensitive enough?
106. Caesarean delivery in relation to birth weight and gestational glucose tolerance
107. Comparison of World Health Organization and National Diabetes Data Group procedures to detect abnormalities of glucose tolerance during pregnancy
108. Toward universal criteria for gestational diabetes: The 75-gram glucose tolerance test in pregnancy
109. Comparison of National Diabetes Data Group and World Health Organization criteria for detecting gestational diabetes mellitus
110. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus
111. Efficacy of screening for gestational diabetes
112. Gestational diabetes screening in a private, midwestern American population
113. 1 gestational diabetes: A meaningful diagnosis?
114. Risk factors for NIDDM in white population: Paris prospective study
115. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests
116. Coronary-heart disease risk and impaired glucose tolerance: The whitehall study
117. Revision of diagnostic criteria for diabetes
118. Hyperglycemia and diabetes mellitus
119. Visual impairment and retinopathy in people with normal glucose tolerance, impaired glucose tolerance and newly diagnosed NIDDM
120. The bedford survey: Observations on retina and leris of subjects with impaired glucose tolerance and in controls with normal glucose tolerance
121. Does hyperglycemia or hyperinsulinaemia characterize the patient with chemical diabetes?
122. Relationship of glycosylated hemoglobin to oral glucose tolerance: Implications for diabetes screening
123. Role of insulin resistance in human disease
124. Diagnosing diabetes mellitus: Do we need new criteria?
125. Screening for NIDDM: Opportunities for detection, treatment and prevention
126. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the U.S. population aged 20-74 yr
127. Why use the oral glucose tolerance test?
128. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes
129. 1C levels for diagnosing diabetes: Diagnostic criteria and performance revisited
130. A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community: The islington diabetes survey
131. Peripheral arterial disease in relation to glycaemic level in elderly Caucasian population: The hoorn study
132. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in general Caucasian population: The hoorn study
133. Determining diabetes prevalence: A rational basis for the use of fasting plasma glucose concentrations?
134. The meta-analysis research group on the diagnosis of diabetes using glycated hemoglobin levels 1996: A clinical approach for the diagnosis of diabetes mellitus: An analysis using glycated hemoglobin levels
135. Tests of glycemia in diabetes (Position Statement)
136. Standards of medical care for patients with diabetes mellitus (Position Statement)
137. Value of ICA512 antibodies for prediction and diagnosis of type 1 diabetes
138. Combined analyses of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives
139. Prediction of type I diabetes in first degree relatives using a combination of insulin, GAD and ICA512bc/IA-2 autoantibodies
140. Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children
141. Undiagnosed NIDDM: Clinical and public health issues
142. Hyperglycemia and microvascular and microvascular disease in diabetes